Literature DB >> 20150180

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties.

G Wozniak-Knopp1, S Bartl, A Bauer, M Mostageer, M Woisetschläger, B Antes, K Ettl, M Kainer, G Weberhofer, S Wiederkum, G Himmler, G C Mudde, F Rüker.   

Abstract

Yeast surface display libraries of human IgG1 Fc regions were prepared in which loop sequences at the C-terminal tip of the CH3 domain were randomized. A high percentage of these library members bound to soluble CD64 and Protein A indicating that the randomization step did not grossly interfere with the overall structure of the displayed Fc. Sorting these libraries by FACS for binders against HER2/neu yielded antigen-specific Fc binders (Fcab; Fc antigen binding) of which one was affinity matured, resulting in Fcab clone H10-03-6 which showed >10-fold improvement in antigen-binding activity versus the parental clone. Pre-equilibrium surface plasmon resonance experiments revealed a K(D) value of 69 nM. H10-03-6 did not react with other members of the HER family and specifically interacted with HER2-positive but not with HER2-negative cells. Importantly, Fcab H10-03-6 elicited potent antibody-dependent cellular cytotoxicity in vitro. Finally, the in vivo half-life in mice was similar to wild-type Fc indicating that the amino acid changes in the CH3 domain did not affect the pharmacokinetic behavior of the recombinant Fc. Our data demonstrate that the Fcab scaffold combines all features of normal antibodies in a small 50 kD homodimeric protein: antigen binding, effector functions and long half-life in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20150180     DOI: 10.1093/protein/gzq005

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  51 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 3.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

4.  The Shark Strikes Twice: Hypervariable Loop 2 of Shark IgNAR Antibody Variable Domains and Its Potential to Function as an Autonomous Paratope.

Authors:  Stefan Zielonka; Martin Empting; Doreen Könning; Julius Grzeschik; Simon Krah; Stefan Becker; Stephan Dickgießer; Harald Kolmar
Journal:  Mar Biotechnol (NY)       Date:  2015-05-24       Impact factor: 3.619

Review 5.  Applications of Yeast Surface Display for Protein Engineering.

Authors:  Gerald M Cherf; Jennifer R Cochran
Journal:  Methods Mol Biol       Date:  2015

Review 6.  Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Authors:  Christian Klein; Claudio Sustmann; Markus Thomas; Kay Stubenrauch; Rebecca Croasdale; Jürgen Schanzer; Ulrich Brinkmann; Hubert Kettenberger; Jörg T Regula; Wolfgang Schaefer
Journal:  MAbs       Date:  2012-08-27       Impact factor: 5.857

Review 7.  T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Authors:  Z Wu; N V Cheung
Journal:  Pharmacol Ther       Date:  2017-08-20       Impact factor: 12.310

Review 8.  Engineered Fc based antibody domains and fragments as novel scaffolds.

Authors:  Tianlei Ying; Rui Gong; Tina W Ju; Ponraj Prabakaran; Dimiter S Dimitrov
Journal:  Biochim Biophys Acta       Date:  2014-05-02

Review 9.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 10.  Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.

Authors:  Weizao Chen; Rui Gong; Tianlei Ying; Ponraj Prabakaran; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Curr Drug Discov Technol       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.